Cutaneous toxicity of autologous bone marrow transplantation in nonseminomatous germ cell tumors
- 1 March 1990
- Vol. 65 (5) , 1143-1145
- https://doi.org/10.1002/1097-0142(19900301)65:5<1143::aid-cncr2820650518>3.0.co;2-v
Abstract
High doses of carboplatin or cisplatin combined with cyclophosphamide and etoposide followed by autologous bone marrow transplantation (ABMT) rescue have been used in the treatment of testicular tumors that have had a bad prognosis. Unusual cutaneous complications, evoking radiation-induced dermatitis, have been seen in two of eight patients with the same regimen. This new type of toxicity seems to be related to high-dose combination chemotherapies. Good results in the treatment of patients with testicular tumors on relapse who continue to respond to chemotherapy lead to the extension of this type of schedule and cutaneous toxicity will probably develop.This publication has 15 references indexed in Scilit:
- INDUCTION OF GRAFT-VERSUS-HOST DISEASE AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATIONThe Lancet, 1989
- Acute Graft-vs-Host DiseaseArchives of Dermatology, 1987
- Carboplatin: the clinical spectrum to dateCancer Treatment Reviews, 1985
- Cis-diammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ-cell tumours: a preliminary reportCancer Treatment Reviews, 1985
- Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial.Journal of Clinical Oncology, 1985
- High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.Journal of Clinical Oncology, 1984
- High–dose melphalan with autologous bone marrow transplant treatment of poor prognosis tumorsCancer, 1983
- The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow supportPublished by Elsevier ,1981
- Cyclophosphamide-Induced UrticariaArchives of internal medicine (1960), 1978
- Cyclophosphamide and pigmentation.BMJ, 1972